MX350230B - Vacunas anticancer de globo h y relacionadas con adyuvantes de glucolipido novedosos. - Google Patents
Vacunas anticancer de globo h y relacionadas con adyuvantes de glucolipido novedosos.Info
- Publication number
- MX350230B MX350230B MX2014004316A MX2014004316A MX350230B MX 350230 B MX350230 B MX 350230B MX 2014004316 A MX2014004316 A MX 2014004316A MX 2014004316 A MX2014004316 A MX 2014004316A MX 350230 B MX350230 B MX 350230B
- Authority
- MX
- Mexico
- Prior art keywords
- globo
- ssea
- immunogenic
- immunogenic compositions
- compositions
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title abstract 3
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 title abstract 2
- 229930186217 Glycolipid Natural products 0.000 title abstract 2
- 229940022399 cancer vaccine Drugs 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 6
- 102000014914 Carrier Proteins Human genes 0.000 abstract 2
- 108010078791 Carrier Proteins Proteins 0.000 abstract 2
- 150000004676 glycans Chemical class 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 abstract 1
- 102000016607 Diphtheria Toxin Human genes 0.000 abstract 1
- 108010053187 Diphtheria Toxin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 abstract 1
- 101710135378 pH 6 antigen Proteins 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001173—Globo-H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Pregnancy & Childbirth (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6196808P | 2008-06-16 | 2008-06-16 | |
| US12/485,546 US20090317411A1 (en) | 2008-06-16 | 2009-06-16 | Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment |
| PCT/US2009/004519 WO2010005598A1 (en) | 2008-06-16 | 2009-08-06 | Globo h and related anti-cancer vaccines with novel glycolipid adjuvants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX350230B true MX350230B (es) | 2017-08-30 |
Family
ID=41431519
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010013932A MX2010013932A (es) | 2008-06-16 | 2009-08-06 | Vacunas anticancer de globo h y relacionadas con adyuvantes de glucolipido novedosos. |
| MX2014004316A MX350230B (es) | 2008-06-16 | 2009-08-06 | Vacunas anticancer de globo h y relacionadas con adyuvantes de glucolipido novedosos. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010013932A MX2010013932A (es) | 2008-06-16 | 2009-08-06 | Vacunas anticancer de globo h y relacionadas con adyuvantes de glucolipido novedosos. |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20090317411A1 (enExample) |
| EP (2) | EP2303286A4 (enExample) |
| JP (4) | JP2011524375A (enExample) |
| KR (1) | KR20110031949A (enExample) |
| CN (1) | CN102065868A (enExample) |
| AU (2) | AU2009268937A1 (enExample) |
| CA (2) | CA2728344A1 (enExample) |
| ES (1) | ES2570630T3 (enExample) |
| MX (2) | MX2010013932A (enExample) |
| NZ (1) | NZ590140A (enExample) |
| WO (2) | WO2010005735A2 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
| CA2723197C (en) | 2008-05-02 | 2017-09-19 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| AU2009268937A1 (en) * | 2008-06-16 | 2010-01-14 | Aj Park | Compositions for inducing immune responses specific to Globo H and SSEA3 and uses thereof in cancer treatment |
| KR101324109B1 (ko) * | 2008-06-16 | 2013-10-31 | 아카데미아 시니카 | Ｇｌｏｂｏ ｈ 및 그의 절편들에 대한 항체의 양에 따른 암 진단방법 |
| EP2318832B1 (en) | 2008-07-15 | 2013-10-09 | Academia Sinica | Glycan arrays on ptfe-like aluminum coated glass slides and related methods |
| US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
| JP5967585B2 (ja) | 2010-05-03 | 2016-08-10 | ディーシービー−ユーエスエー エルエルシーＤｃｂ−Ｕｓａ Ｌｌｃ | ワクチンとして使用される無毒化大腸菌易熱性エンテロトキシン（ｌｔ）との多糖結合 |
| JP6050227B2 (ja) * | 2010-06-11 | 2016-12-21 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | 多価糖ペプチド構築物およびその使用 |
| DK2608796T3 (en) * | 2010-08-05 | 2019-03-18 | Seattle Genetics Inc | Inhibition of protein fucosylation in vivo using fucose analogues |
| GB201013767D0 (en) * | 2010-08-17 | 2010-09-29 | Isis Innovation | Identification of ligands and their use |
| US20120288525A1 (en) | 2011-05-11 | 2012-11-15 | Chakravarty Sumana | Pharmaceutical compositions comprising attenuated plasmodium sporozoites and glycolipid adjuvants |
| JP6187939B2 (ja) * | 2012-03-08 | 2017-08-30 | 学校法人産業医科大学 | がんの悪性度の試験方法、ならびに多能性を有する造腫瘍細胞およびその調製方法 |
| US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
| EP2885311B1 (en) | 2012-08-18 | 2020-01-01 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
| US9547009B2 (en) | 2012-08-21 | 2017-01-17 | Academia Sinica | Benzocyclooctyne compounds and uses thereof |
| US10350228B2 (en) | 2012-08-23 | 2019-07-16 | Seattle Genetics, Inc. | Treatment of sickle cell disease and inflammatory conditions |
| EP3792272A1 (en) * | 2013-01-04 | 2021-03-17 | OBI Pharma, Inc. | Vaccines with higher carbohydrate antigen density and novel saponin adjuvant |
| EP2993182B1 (en) | 2013-05-02 | 2020-10-14 | National Institute of Advanced Industrial Science and Technology | Immunity inducer for saccharide antigens |
| US10086054B2 (en) | 2013-06-26 | 2018-10-02 | Academia Sinica | RM2 antigens and use thereof |
| US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
| GB201313352D0 (en) | 2013-07-26 | 2013-09-11 | Isis Innovation | Identification of peptide ligands |
| WO2015035337A1 (en) | 2013-09-06 | 2015-03-12 | Academia Sinica | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS |
| KR20160055861A (ko) | 2013-09-17 | 2016-05-18 | 오비아이 파머 인코퍼레이티드 | 암치료에서 면역반응을 유도하기 위한 탄수화물 백신의 조성물 |
| US9982041B2 (en) * | 2014-01-16 | 2018-05-29 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| WO2016114819A1 (en) * | 2015-01-16 | 2016-07-21 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| WO2015143123A2 (en) | 2014-03-19 | 2015-09-24 | Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation | Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof |
| EP3129767B1 (en) | 2014-03-27 | 2021-09-01 | Academia Sinica | Reactive labelling compounds and uses thereof |
| BR112016020009A2 (pt) | 2014-04-10 | 2017-10-17 | Obi Pharma Inc | anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma |
| CN106573971A (zh) | 2014-05-27 | 2017-04-19 | 中央研究院 | 抗cd20醣抗体及其用途 |
| AU2015267051B2 (en) | 2014-05-27 | 2022-03-17 | Academia Sinica | Fucosidase from bacteroides and methods using the same |
| CA2950440A1 (en) * | 2014-05-27 | 2015-12-03 | Academia Sinica | Anti-her2 glycoantibodies and uses thereof |
| US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| CN106714829A (zh) | 2014-05-28 | 2017-05-24 | 中央研究院 | 抗TNF‑α醣抗体及其用途 |
| GB201414021D0 (en) * | 2014-08-07 | 2014-09-24 | Nascient Ltd | Biological materials and uses thereof |
| CN106573962B (zh) * | 2014-08-22 | 2020-06-05 | 中央研究院 | 新颖的聚糖共轭物及其用途 |
| US9879042B2 (en) | 2014-09-08 | 2018-01-30 | Academia Sinica | Human iNKT cell activation using glycolipids |
| CN107427564A (zh) * | 2014-09-15 | 2017-12-01 | 台湾浩鼎生技股份有限公司 | 免疫原性/治疗性糖缀合物组合物及其用途 |
| US20170348414A1 (en) * | 2014-09-15 | 2017-12-07 | Wayne State University | Novel synthetic anticancer, antifungal, and antibacterial vaccines |
| US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
| US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| CA2972731A1 (en) * | 2015-01-24 | 2016-07-28 | Chi-Huey Wong | Cancer markers and methods of use thereof |
| AU2015378564A1 (en) | 2015-01-24 | 2017-07-13 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
| EP3250590B1 (en) | 2015-01-30 | 2021-09-15 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced anti-ssea4 antibody efficacy |
| CN105067813A (zh) * | 2015-07-23 | 2015-11-18 | 丁晓昆 | 一种快速检测t-合酶活性的方法 |
| KR20180050339A (ko) | 2015-09-04 | 2018-05-14 | 오비아이 파머 인코퍼레이티드 | 글리칸 어레이 및 사용 방법 |
| KR20180114210A (ko) | 2016-03-08 | 2018-10-17 | 아카데미아 시니카 | N-글리칸의 모듈 합성 방법 및 그의 어레이 |
| US11041017B2 (en) | 2016-03-29 | 2021-06-22 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| AU2017252128B2 (en) * | 2016-04-22 | 2024-06-06 | Obi Pharma, Inc. | Cancer immunotherapy by immune activation or immune modulation via Globo series antigens |
| KR20230117482A (ko) * | 2016-07-27 | 2023-08-08 | 오비아이 파머 인코퍼레이티드 | 면역원성/치료 글리칸 조성물 및 그의 용도 |
| CN110062767B (zh) * | 2016-07-29 | 2023-07-11 | 台湾浩鼎生技股份有限公司 | 人抗体、药物组合物和方法 |
| US10538592B2 (en) | 2016-08-22 | 2020-01-21 | Cho Pharma, Inc. | Antibodies, binding fragments, and methods of use |
| TW201825522A (zh) * | 2016-09-23 | 2018-07-16 | 張志隆 | 抗-globo h 抗體 |
| TWI822055B (zh) * | 2016-11-21 | 2023-11-11 | 台灣浩鼎生技股份有限公司 | 共軛生物分子、醫藥組成物及方法 |
| WO2019217951A1 (en) * | 2018-05-11 | 2019-11-14 | Obi Pharma Inc. | Method for predicting human immune response |
| WO2020006176A1 (en) | 2018-06-27 | 2020-01-02 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
| JP7319362B2 (ja) | 2018-11-02 | 2023-08-01 | シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド | マクロフィリン結合医薬アッセイに使用するための結合競合剤およびその使用方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544952B1 (en) * | 1994-03-15 | 2003-04-08 | Sloan-Kettering Institute For Cancer Research | Synthesis of glycoconjugates of the globo-H epitope and uses thereof |
| US20040126381A1 (en) * | 1996-04-23 | 2004-07-01 | Xin-Xing Gu | Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella |
| AU750701C (en) * | 1997-04-16 | 2003-03-20 | Sloan-Kettering Institute For Cancer Research | Alpha-O-linked glycoconjugates, methods of preparation and uses thereof |
| CA2401580A1 (en) * | 2000-02-29 | 2001-09-07 | Sloan-Kettering Institute For Cancer Research | Affinity matrix bearing tumor-associated antigens |
| GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| GB0024200D0 (en) * | 2000-10-03 | 2000-11-15 | Smithkline Beecham Sa | Component vaccine |
| JP2004534088A (ja) | 2001-07-06 | 2004-11-11 | スローン−ケッタリング・インスティテュート・フォア・キャンサー・リサーチ | 癌のための多価コンジュゲートワクチン |
| JP2005500336A (ja) * | 2001-07-25 | 2005-01-06 | ニューヨーク・ユニバーシティ | 感染および癌に対するワクチンのためのアジュバントとしてのグリコシルセラミドの使用 |
| US7132101B2 (en) * | 2002-02-27 | 2006-11-07 | Duquesne University Of The Holy Ghost | Compositions and methods for eliciting an immune response to gram-negative bacterial infections |
| AU2003277021A1 (en) * | 2002-09-27 | 2004-04-19 | Biomira, Inc. | Glycosylceramide analogues |
| US20060035267A1 (en) * | 2003-04-09 | 2006-02-16 | Livingston Philip O | Optimal polyvalent vaccine for cancer |
| GB0313916D0 (en) * | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| WO2006068758A2 (en) * | 2004-11-19 | 2006-06-29 | The Scripps Research Institute | Detection, prevention and treatment of breast cancer |
| GB0428394D0 (en) * | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| US7923013B2 (en) | 2004-12-28 | 2011-04-12 | The Rockefeller University | Glycolipids and analogues thereof as antigens for NKT cells |
| AU2005322027B2 (en) | 2004-12-28 | 2013-09-12 | The Rockefeller University | Glycolipids and analogues thereof as antigens for NK Tcells |
| KR100764678B1 (ko) * | 2005-07-13 | 2007-10-09 | 재단법인서울대학교산학협력재단 | 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물 |
| US7794722B2 (en) * | 2006-06-30 | 2010-09-14 | The Scripps Research Institute | Adjuvants and methods of use |
| CN101225383B (zh) * | 2007-01-15 | 2011-10-12 | 燕秋 | 用于抑制LeY糖抗原合成的岩藻糖基转移酶Ⅰ和Ⅳ的RNA干涉序列及重组干涉质粒 |
| WO2008103392A2 (en) * | 2007-02-21 | 2008-08-28 | Vaccinex, Inc. | Modulation of nkt cell activity with antigen-loaded cdid molecules |
| GB0703369D0 (en) * | 2007-02-21 | 2007-03-28 | Health Prot Agency | Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines |
| TW200911274A (en) * | 2007-04-13 | 2009-03-16 | Academia Sinica | Alpha-galatosyl ceramide analogs and their use as immunotherapies |
| IN2009KN04098A (enExample) * | 2007-06-04 | 2015-08-28 | Novartis Ag | |
| AU2009268937A1 (en) * | 2008-06-16 | 2010-01-14 | Aj Park | Compositions for inducing immune responses specific to Globo H and SSEA3 and uses thereof in cancer treatment |
| US8383767B2 (en) * | 2008-06-27 | 2013-02-26 | Academia Sinica | Immunogenic protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain |
| US7928077B2 (en) * | 2008-07-11 | 2011-04-19 | Academia Sinica | Alpha-galactosyl ceramide analogs and their use as immunotherapies |
-
2009
- 2009-06-16 AU AU2009268937A patent/AU2009268937A1/en not_active Abandoned
- 2009-06-16 EP EP09794927A patent/EP2303286A4/en not_active Withdrawn
- 2009-06-16 US US12/485,546 patent/US20090317411A1/en not_active Abandoned
- 2009-06-16 CN CN2009801237219A patent/CN102065868A/zh active Pending
- 2009-06-16 WO PCT/US2009/047537 patent/WO2010005735A2/en not_active Ceased
- 2009-06-16 CA CA2728344A patent/CA2728344A1/en not_active Abandoned
- 2009-06-16 JP JP2011513760A patent/JP2011524375A/ja active Pending
- 2009-06-16 KR KR1020117001004A patent/KR20110031949A/ko not_active Withdrawn
- 2009-08-06 MX MX2010013932A patent/MX2010013932A/es active IP Right Grant
- 2009-08-06 US US12/537,129 patent/US8268969B2/en active Active
- 2009-08-06 CA CA2728341A patent/CA2728341C/en active Active
- 2009-08-06 MX MX2014004316A patent/MX350230B/es unknown
- 2009-08-06 WO PCT/US2009/004519 patent/WO2010005598A1/en not_active Ceased
- 2009-08-06 JP JP2011514633A patent/JP5628158B2/ja active Active
- 2009-08-06 AU AU2009269127A patent/AU2009269127B2/en active Active
- 2009-08-06 ES ES09789075T patent/ES2570630T3/es active Active
- 2009-08-06 EP EP09789075.0A patent/EP2310047B1/en active Active
- 2009-08-06 NZ NZ590140A patent/NZ590140A/en unknown
-
2012
- 2012-08-07 US US13/568,510 patent/US9028836B2/en active Active
-
2014
- 2014-02-26 JP JP2014035431A patent/JP5795655B2/ja active Active
-
2015
- 2015-04-01 US US14/675,838 patent/US9603913B2/en active Active
- 2015-08-11 JP JP2015159196A patent/JP6151319B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2303286A4 (en) | 2011-12-28 |
| JP5628158B2 (ja) | 2014-11-19 |
| CN102065868A (zh) | 2011-05-18 |
| US20150273034A1 (en) | 2015-10-01 |
| US9603913B2 (en) | 2017-03-28 |
| EP2303286A2 (en) | 2011-04-06 |
| US8268969B2 (en) | 2012-09-18 |
| WO2010005735A2 (en) | 2010-01-14 |
| JP2011524417A (ja) | 2011-09-01 |
| US20100136042A1 (en) | 2010-06-03 |
| JP2011524375A (ja) | 2011-09-01 |
| JP2014144958A (ja) | 2014-08-14 |
| EP2310047B1 (en) | 2016-03-30 |
| JP6151319B2 (ja) | 2017-06-21 |
| US20090317411A1 (en) | 2009-12-24 |
| AU2009268937A1 (en) | 2010-01-14 |
| JP2016020363A (ja) | 2016-02-04 |
| CA2728341C (en) | 2019-07-02 |
| JP5795655B2 (ja) | 2015-10-14 |
| US9028836B2 (en) | 2015-05-12 |
| WO2010005735A3 (en) | 2010-03-18 |
| ES2570630T3 (es) | 2016-05-19 |
| EP2310047A1 (en) | 2011-04-20 |
| AU2009269127A1 (en) | 2010-01-14 |
| NZ590140A (en) | 2012-07-27 |
| CA2728341A1 (en) | 2010-01-14 |
| KR20110031949A (ko) | 2011-03-29 |
| CA2728344A1 (en) | 2010-01-14 |
| WO2010005598A1 (en) | 2010-01-14 |
| US20120328646A1 (en) | 2012-12-27 |
| AU2009269127B2 (en) | 2013-12-05 |
| MX2010013932A (es) | 2013-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX350230B (es) | Vacunas anticancer de globo h y relacionadas con adyuvantes de glucolipido novedosos. | |
| WO2010104749A8 (en) | Antigen presenting cell targeted cancer vaccines | |
| MX2011009438A (es) | Anticuerpos anti-cd40 y usos de los mismos. | |
| MX337397B (es) | Vacunas anti-virales dirigidas a celulas que presentan antigeno. | |
| GB0428394D0 (en) | Saccharide conjugate vaccines | |
| WO2011032161A8 (en) | Vaccines directed to langerhans cells | |
| MX2007002787A (es) | Adyuvante de glicosilceramida para antigenos de sacarido. | |
| WO2007067681A3 (en) | Immunostimulatory compositions and methods | |
| EA035991B9 (ru) | Новый полисахарид и его применения | |
| MX2019014829A (es) | Vacunas de conjugado multivalente con polisacáridos de conjugado bivalente o multivalente que proporcionan inmunogenicidad y avidez mejoradas. | |
| EA201070329A1 (ru) | Векторы и конструкции для доставки гриппозного антигена | |
| MX2019014833A (es) | Conjugacion de anticuerpo-farmaco especifica de sitio mediante glicoingenieria. | |
| FR2919804B1 (fr) | Composition et vaccin therapeutique anti-tumoral | |
| GB2434367A (en) | Improved vaccines | |
| WO2014107652A3 (en) | Vaccines with higher carbohydrate antigen density and novel saponin adjuvant | |
| SG162817A1 (en) | Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma | |
| SA521421049B1 (ar) | مستقبلات خيمرية لمستضدات بشروية ستة عبر الغشاء للبروستاتة 1 وطرق استخدامها | |
| MX2011009359A (es) | Conjugados hapteno-portador con toxinas bacterianas que tienen un peptido señal como portador, y su uso en composiciones inmunogenas. | |
| MX2010001237A (es) | Nuevos anticuerpos. | |
| WO2009114085A3 (en) | Allogeneic cancer cell-based immunotherapy | |
| PH12022551000A1 (en) | Directed conjugation technologies | |
| HK1218860A1 (zh) | 卵巢癌疫苗及接种方法 | |
| MX2019006105A (es) | Conjugados de vmen-antigeno y uso de los mismos. | |
| WO2022066965A3 (en) | Immunotherapy targeting sox2 antigens | |
| WO2022197890A8 (en) | Anti-alpp/alppl2 antibodies and antibody-drug conjugates |